Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 12,700 shares, a decline of 13.0% from the January 15th total of 14,600 shares. Based on an average daily trading volume, of 69,100 shares, the days-to-cover ratio is currently 0.2 days.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM traded up $0.22 during mid-day trading on Friday, hitting $9.91. The stock had a trading volume of 70,402 shares, compared to its average volume of 62,683. The firm has a market cap of $69.07 million, a P/E ratio of -4.24 and a beta of 1.03. The business has a fifty day moving average price of $10.00 and a 200-day moving average price of $10.58. Global X Genomics & Biotechnology ETF has a 52 week low of $9.40 and a 52 week high of $12.53.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at $50,000. Oxinas Partners Wealth Management LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter valued at $103,000. Sanctuary Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter valued at $104,000. Sei Investments Co. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 4th quarter valued at $114,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 11.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after purchasing an additional 1,265 shares during the period. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.